GlassScriptPhysician profile
Archana Kokroo
NPI 1174564686
$1,709.91
in general payments reported to CMS, 2019-2025
26 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $29.42 · 2022: $174 · 2023: $267 · 2024: $329 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $191.43 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Bausch Health US, LLC | $185.97 | 2022-2025 | Wellbutrin, Aplenzin |
| Astrazeneca Pharmaceuticals LP | $183.79 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $163.04 | 2019-2024 | |
| Amarin Pharma, INC. | $122.95 | 2019 | |
| Astellas Pharma US INC | $102.73 | 2019-2023 | Veozah, Myrbetriq |
| Amgen INC. | $97.24 | 2019-2025 | Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $93.74 | 2024-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $79.64 | 2019-2025 | Zoryve |
| Novo Nordisk INC | $76.81 | 2019-2022 | |
| Mylan Specialty L.P. | $44.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.36 | 2019 | |
| Abbott Laboratories | $42.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.73 | 2023-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $29.36 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $24.76 | 2023 | Adlarity |
| Ibsa Pharma INC. | $23.26 | 2019 | |
| Dexcom, INC. | $21.58 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $20.73 | 2024 | |
| Boston Scientific Corporation | $19.87 | 2024 | Bodyguardian |
| Linus Health, INC. | $19.69 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.66 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $18.07 | 2023 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $16.59 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $16.23 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Kokroo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.